Kishimoto Takashi Kei
Chief Scientific Officer at RNAC
- Sold, on record
- $227k
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jan 5, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- RNACCartesian Therapeutics, Inc.Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale RNACUnusualDec 28 2016
Sold 10,000 shares at $17.55 ($176k)
Kishimoto Takashi Kei, Chief Scientific Officer
Sold 100% of holdings ($176k position)0 shares leftFirst sale on recordFiling
- 2 Form 4 sale RNACPlan not statedOct 13 +1750 days
Sold 3,892 shares at $4.39 ($17k)
Kishimoto Takashi Kei, Chief Scientific Officer
Sold 2% of holdings ($853k position)190,389 shares leftFirst sale on recordFiling
- 3 Form 4 sale RNACPlan not statedDec 10 +58 days
Sold 4,370 shares at $2.99 ($13k)
Kishimoto Takashi Kei, Chief Scientific Officer
Sold 2.1% of holdings ($610k position)199,769 shares leftFiling
- 4 Form 4 sale RNACPlan not statedJan 5 +26 days
Sold 3,416 shares at $3.09 ($11k)
Kishimoto Takashi Kei, Chief Scientific Officer
Sold 1.3% of holdings ($840k position)268,353 shares leftFiling
- 5 Form 4 sale RNACPlan not statedJan 5 +365 days
Sold 9,784 shares at $1.13 ($11k)
Kishimoto Takashi Kei, Chief Scientific Officer
Sold 2.6% of holdings ($423k position)364,316 shares left2.5x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (5)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2023 | RNAC | Chief Scientific Officer | Form 4 sale | 9,784 | $11k | 2.6% | Plan not stated | SEC |
| Jan 5, 2022 | RNAC | Chief Scientific Officer | Form 4 sale | 3,416 | $11k | 1.3% | Plan not stated | SEC |
| Dec 10, 2021 | RNAC | Chief Scientific Officer | Form 4 sale | 4,370 | $13k | 2.1% | Plan not stated | SEC |
| Oct 13, 2021 | RNAC | Chief Scientific Officer | Form 4 sale | 3,892 | $17k | 2.0% | Plan not stated | SEC |
| Dec 28, 2016 | RNAC | Chief Scientific Officer | Form 4 sale | 10,000 | $176k | 100.0% | Unusual | SEC |